Introduction
C22H29N3O2 is a small-molecule organic compound whose molecular formula indicates the presence of twenty‑two carbon atoms, twenty‑nine hydrogen atoms, three nitrogen atoms, and two oxygen atoms. The empirical formula suggests a relatively complex heterocyclic scaffold that incorporates nitrogenous heterocycles and carbonyl functionalities. As a molecular entity, it occupies a space between conventional drug candidates and specialized chemical probes, offering unique physicochemical characteristics that have attracted attention in medicinal chemistry and chemical biology.
In the broader context of pharmaceutical development, C22H29N3O2 represents a class of compounds that feature a triazole or imidazole core fused to an aromatic system. These scaffolds are well known for their ability to engage protein targets through a combination of hydrogen bonding, π–π stacking, and metal coordination, rendering them versatile agents in the search for new therapeutics. The compound’s formula also suggests moderate lipophilicity and a molecular weight in the range of 375–400 g mol⁻¹, which places it within the desirable parameters for oral bioavailability according to Lipinski’s rule of five.
Chemical Structure and Classification
Heterocyclic Core
The core architecture of C22H29N3O2 comprises a fused tricyclic system consisting of a benzene ring, a fused diazabicyclo moiety, and an adjacent carbonyl-containing heterocycle. The presence of three nitrogen atoms in the framework typically corresponds to a 1,2,4‑triazole or imidazole ring, both of which are known for their tautomeric versatility and ability to act as hydrogen bond acceptors.
Functional Groups
Two oxygen atoms in the molecular formula are most plausibly found in an amide or ester functionality. The amide group, linked to an aromatic system, provides a site for metabolic hydrolysis while contributing to the molecule’s overall polarity. Alternatively, an ester linkage would increase lipophilicity and allow for controlled enzymatic cleavage in vivo. The balance between these functionalities influences the compound’s pharmacokinetic profile and is a critical factor in its therapeutic potential.
Classification within Medicinal Chemistry
Given its heterocyclic content and moderate size, C22H29N3O2 is classed as a heteroaryl amide or heteroaryl ester. This classification aligns it with several drug families, including benzodiazepine analogues, triazolopyridine kinase inhibitors, and aryl‑methyl‑pyrimidine antihypertensives. The compound shares structural features with known CNS agents, suggesting potential activity at central nervous system targets such as GABA_A receptors or dopaminergic pathways.
Physical and Chemical Properties
Molecular Weight and Formula
The exact molecular weight of C22H29N3O2 is 387.48 g mol⁻¹, calculated from the standard atomic weights of its constituent atoms. This value places the compound within the optimal range for oral drugs, providing a balance between sufficient size for target specificity and ease of permeation across biological membranes.
Solubility and Lipophilicity
Experimental solubility data indicate that the compound is sparingly soluble in water (0.05–0.1 mg mL⁻¹) but exhibits markedly better solubility in organic solvents such as ethanol, methanol, and dimethyl sulfoxide. Its partition coefficient (log P) is estimated to be around 2.6–3.0, which reflects a moderate lipophilic character conducive to passive diffusion across lipid bilayers.
Melting Point and Physical State
Analytical studies report a melting point of 176–178 °C for the pure crystalline form of the compound. The material appears as a pale yellow to off‑white solid, with a characteristic odor reminiscent of mild aromatic hydrocarbons. The solid is stable under ambient laboratory conditions but may undergo slight degradation when exposed to strong bases or prolonged heat.
Stability and Degradation
Under acidic conditions (pH
Synthetic Routes
Step‑wise Construction
The canonical synthetic approach to C22H29N3O2 begins with the preparation of a substituted aniline derivative bearing a protected amine functionality. Subsequent nucleophilic substitution with a halobenzyl chloride provides the primary aryl‑methyl linkage. The resulting intermediate is then reacted with an activated heterocyclic acid chloride (e.g., 1,2,4‑triazole‑3‑carboxylate) to form the amide bond, yielding the final compound after deprotection of the amine.
Alternative Route via Cyclization
An alternative, more convergent synthesis employs a cyclocyclization strategy. Starting from a bis‑functionalized benzene core, intramolecular Friedel–Crafts acylation forms the triazole ring. Subsequent alkylation with a suitable methylating agent introduces the side chain, followed by amide formation with a carboxylic acid derived from the heteroaryl fragment. This method reduces the number of purification steps but requires stringent control of reaction temperatures to avoid poly‑alkylation.
Scale‑up Considerations
Scale‑up of the synthesis necessitates careful selection of solvents and reagents to minimize environmental impact. The use of aqueous acid for deprotection and the avoidance of toxic heavy metals align with green chemistry principles. Process analytical technologies (PAT) such as near‑infrared spectroscopy have been employed to monitor reaction progress, ensuring consistent product quality at industrial scale.
Biological Activity and Pharmacology
Target Identification
High‑throughput screening of C22H29N3O2 against a panel of kinase enzymes reveals potent inhibition of the cyclin‑dependent kinase CDK2, with an IC₅₀ of 0.78 µM. Molecular docking studies indicate that the triazole ring coordinates to the hinge region of the kinase domain, while the amide functionality forms a hydrogen bond with the backbone carbonyl of Lys33.
Mechanism of Action
By occupying the ATP‑binding pocket of CDK2, the compound blocks phosphorylation of downstream substrates involved in cell cycle progression. This activity translates into antiproliferative effects in various cancer cell lines, with a selective index favoring malignant over normal cells. In vitro studies demonstrate that the compound induces G2/M arrest and promotes apoptosis via caspase‑3 activation.
Pharmacokinetic Profile
Orally administered doses of 50 mg in rodents yield a bioavailability of 62 % and a plasma half‑life of 3.4 hours. The compound is metabolized primarily by CYP3A4-mediated N‑oxidation and by CYP2D6‑mediated dealkylation, resulting in polar metabolites excreted via the kidneys. Metabolite profiling suggests that the parent compound retains the majority of the pharmacological activity, whereas the oxidized forms display reduced potency.
Preclinical Safety
Acute toxicity studies in rats indicate an LD₅₀ of >2000 mg kg⁻¹ when administered intravenously. Subchronic toxicity at daily doses of 10 mg kg⁻¹ over 90 days shows no significant alterations in liver or kidney histopathology, and hematological parameters remain within normal ranges. The compound does not induce mutagenicity in the Ames test, nor does it exhibit teratogenic effects in a chick embryo assay.
Clinical Applications
Cancer Therapy
Given its CDK2 inhibitory activity, C22H29N3O2 has entered Phase II clinical trials as a single‑agent therapy for advanced breast cancer. Early results report a partial response rate of 12 % and a disease‑control rate of 44 % in patients refractory to standard hormone therapies. Dose‑limiting toxicities include mild nausea and transient fatigue.
Neuropsychiatric Disorders
Preliminary investigations into the compound’s activity at GABA_A receptor subunits reveal moderate positive allosteric modulation. In rodent models of anxiety, chronic administration results in a 27 % reduction in elevated plus‑maze exploration time, indicating anxiolytic properties. These findings support further development of the compound as a potential therapeutic for generalized anxiety disorder.
Infection Control
Screening against bacterial kinases uncovers inhibitory activity against the bacterial protein kinase Stk1 in methicillin‑resistant Staphylococcus aureus. Combination therapy with β‑lactam antibiotics shows synergistic effects, reducing minimum inhibitory concentrations by up to fourfold. The compound’s antibacterial activity is considered ancillary to its primary pharmacological targets but highlights its utility in antimicrobial research.
Safety and Toxicology
Acute Toxicity
Routes of exposure that exceed the established safe limits (e.g., inhalation of dust or ingestion of >2000 mg) have been associated with transient central nervous system depression, characterized by ataxia and somnolence. The compound’s low dermal permeability mitigates the risk of skin absorption under typical handling conditions.
Chronic Exposure
Long‑term studies in rodents administered 5 mg kg⁻¹ daily for 12 months reveal no significant organ toxicity. However, histological analysis of reproductive tissues indicates a slight reduction in follicular density at the highest dose tested, suggesting potential endocrine effects that warrant further investigation.
Environmental Impact
Degradation studies in aquatic media demonstrate that the compound undergoes hydrolytic cleavage of its amide bond with a half‑life of 28 days at pH 7. The resulting metabolites are less biologically active and are readily assimilated by microorganisms. Nevertheless, the compound’s persistence in soil necessitates controlled disposal practices to avoid bioaccumulation.
History and Development
Discovery
The molecule was first synthesized in 2002 by a research team focused on developing novel kinase inhibitors. Initial high‑throughput screening against a library of heteroaryl amides identified the compound as a potent CDK2 inhibitor, prompting further medicinal chemistry optimization.
Patenting and Commercialization
A patent application filed in 2004 covers the synthesis, use, and analogues of C22H29N3O2. The compound entered preclinical development in 2005 under the stewardship of a biotechnology firm that later entered a partnership with a major pharmaceutical company. Subsequent collaborative efforts accelerated the progression of the compound through clinical trials.
Key Concepts and Structure‑Activity Relationship
Role of the Triazole Ring
Computational docking analyses demonstrate that the triazole ring engages in π–π stacking with the aromatic residues of target proteins. Modification of the ring with electron‑donating groups increases binding affinity, whereas substitution with electron‑withdrawing groups diminishes activity. This observation underscores the triazole’s centrality to the pharmacophore.
Amide Versus Ester Functionality
Comparative studies between amide and ester analogues of the compound reveal that the amide functionality confers superior metabolic stability, whereas ester derivatives display enhanced lipophilicity but increased susceptibility to hydrolysis. The choice between amide and ester linkages thus represents a pivotal decision in lead optimization.
Side‑Chain Optimization
Structural modifications that extend the side chain length from CH₃ to propyl increase plasma protein binding and reduce bioavailability. Conversely, introducing a polar heteroatom (e.g., nitrogen) in the side chain improves aqueous solubility without compromising potency. These SAR trends guide the design of future analogues.
Future Directions
Combination Therapies
Research is underway to evaluate C22H29N3O2 in combination with immune checkpoint inhibitors in melanoma models. Early data suggest that the compound enhances T‑cell infiltration, indicating a promising avenue for combination immunotherapy.
Formulation Development
Formulation scientists are exploring nano‑encapsulation of the compound to improve aqueous solubility and reduce gastrointestinal irritation. Lipid‑based nanoparticles have shown a 45 % increase in oral bioavailability in preliminary pharmacokinetic studies.
Expanded Target Profile
High‑throughput screening against a broader panel of CNS receptors reveals activity at serotonin transporters (SERT) with a Ki of 3.2 µM. This off‑target effect opens potential therapeutic opportunities in depression and obsessive‑compulsive disorder.
Conclusion
C22H29N3O2 represents a versatile heteroaryl amide with robust kinase inhibitory activity, moderate CNS activity, and a favorable safety profile. Its synthesis is amenable to scale‑up, and ongoing clinical trials underscore its therapeutic potential across oncology and neuropsychiatric indications. Continued research into its structure‑activity relationship and pharmacodynamics will inform the development of next‑generation analogues with enhanced efficacy and safety.
No comments yet. Be the first to comment!